Boston Scientific (NYSE:BSX) today reported first-quarter financial results that came in ahead of the Wall Street forecast.
CEO Mike Mahoney told investors that the lowered forecast reflects challenges for several businesses, including ...
On April 22, 2026, investors weigh a rare combo of earnings strength and softer long-term targets reshaping this medtech ...
Despite Boston’s Q1 performance denoting a YoY rise of 11.2%, the company has trimmed its full-year growth outlook by 2% at the top-end.
Made Scientific, Inc., a U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Regenicin, ...
Boston Scientific (NYSE:BSX | BSX Price Prediction) stock has taken a beating in 2026 after management cut full-year guidance ...
April 22 (Reuters) - Medical device maker Boston Scientific cut its annual profit forecast on Wednesday, overshadowing a ...
AI has already proved itself a valuable scientific tool. Could it take on a more central role in the research process?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results